FTC's antitrust loss may set pharma precedent
One drugmaker prevails in an antitrust case, and all drugmakers could benefit.
One drugmaker prevails in an antitrust case, and all drugmakers could benefit. Such is the story with the Federal Trade Commission's recent failure to smack down Ovation Pharmaceuticals (now Lundbeck), The National Law Journal reports. The FTC had accused Ovation of monopolizing treatments for a heart defect in premature infants, then hiking prices by 1,300 percent.
Ovation bought the rights to Indocin IV from Merck in 2005, then snapped up rights to the only other medicine for that heart defect, Abbott Laboratories' experimental NeoProfen. After that acquisition closed, Ovation raised the price of Indocin to $500 per vial from $36 per vial. The FTC stepped in after a U.S. senator and Minnesota doctors called on the agency to act.
But the FTC lawsuit didn't impress Judge Joan Ericksen, and it's her 40-page decision that stands to have a ripple effect for pharma. Ericksen decided that Indocin and NeoProfen didn't occupy the same drug market, even though the two drugs
Related News
-
News Panaxia's medical cannabis facility in Malta gains EU-GMP standard
This second facility gives the company a significant power multiplier for export capacity and geographical reach -
News CPhI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipients
Ahead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPhI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor... -
News Pharma Explained: What is Quality Risk Management & cGMPs?
Need clarity on determining your QA from your QbD and your cGMPs? You’re not alone! In our new Pharma Explained series from CPhI, we bring you clear cut definitions from industry experts on a myriad of Pharma Terms, delivered in bitesize video presenta... -
News Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations
Dr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPhI Festival of Pharma -
News Successful MHRA regulatory inspection for Scottish CMO Symbiosis
Inspection conducted remotely using video-conferencing and an online private document sharing platform. -
News Mylan and development partner win significant EPO ruling related to Copaxone
Decision clears legal pathway to expand access for patients living with multiple sclerosis in markets across Europe. -
News COVID-19 ushers in age of digital, flexible EU pharmaceutical regulation
The pandemic that has swept over the world in 2020 has caused huge disruption to the European pharmaceutical industry's regulatory procedures and supply chain management. But the crisis has also provided a platform for a learning process for the sy... -
News Europe's CHMP recommends suspension of medicines tested by Panexcell over flawed studies
The European Medicines Agency's human medicines committee (CHMP) has recommended the suspension of European marketing authorizations of generic medicines tested by Panexcell Clinical Laboratories at its site in Mumbai, India, citing irregularities in h...
Position your company at the heart of the global Pharma industry with a CPhI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPhI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance